Despite last quarter's price drop, ANI Pharmaceuticals, Inc. is seen promising due to strong share price momentum. The firm's shift from loss to profitability in the past three years signals good performance and growth.
The company's weak ROE, falling net income, and retention of most profits without sufficient growth may not benefit investors. Future earnings, though, are projected to grow.
$ANI Pharmaceuticals(ANIP.US)$why in the world are people selling for the bid...at least pump up the value with higher ask prices....this stock has a lot more value to run with
ANI Pharmaceuticals股票討論區
2023Q1營收暴增65.6%,營業利潤和淨利潤均扭虧,從季報環比看,近5個月營收和利潤的季報環比持續增長,是個扭虧的好跡象。
目前僅有一個月的盈利數據,可以多等幾份季報再做判斷。
• $La-Z-Boy(LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $輝瑞(PFE.US)$)
• $Ikena Oncology(IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
• $Repare Therapeutics(RPTX.US)$ +26.4% (announces worldwide license and collaboration agreement with Roche for camonsertib)
• $Chewy(CHWY.US)$+19.8% (Chewy stock soars on earnings. Here's what really mattered)
• $UiPath(PATH.US)$ +11.7% ( reported first-quarter revenue growth of 32% year-over-year to $245.1 million)
• $Pure Storage(PSTG.US)$ +10.6% (In reaction to earnings)
• $Credo Technology(CRDO.US)$ +10.2% (In reaction ...
ANI Pharmaceuticals, Inc. Announces Pricing of $75 Million Public Offering of Common Stock
https://www.businesswire.com/news/home/20211103006382/en/ANI-Pharmaceuticals-Inc.-Announces-Pricing-of-75-Million-Public-Offering-of-Common-Stock
wait for afternoon
暫無評論